1. Introduction {#sec1}
===============

The dermal variants of leishmaniasis present either as single ulcerated lesion i.e. localized self-healing cutaneous leishmaniasis (LCL) caused by *Leishmania braziliensis, L. amazonensis* and *L. mexicana,* or as lesions that are disseminated multiple ulcers and papules involving the oronasal mucosa, termed as mucocutaneous leishmaniasis (MCL), causative species being *L. braziliensis* and *L. panamensis* or in a generalised, diffuse pattern termed as diffuse cutaneous leishmaniasis (DCL), species involved being *L. mexicana* and *L. amazonensis* ([@bib47]). In the Old world, CL is generally self-healing and is caused by *L. major, L. tropica* and *L. aethiopica* ([@bib27]). An interesting dermal variant caused by *L. donovani* occurs in Sri Lanka and appears as small erythematous papules which can also assume a nodulo-ulcerative appearance ([@bib24]). Additionally, in North-Western India, nodulo-ulcerative lesions with crusted plaques caused by *L. tropica* have been reported ([@bib1]).

To add further complexity to dermal leishmaniasis is Post Kala-azar Dermal Leishmaniasis (PKDL), which appears as a dermal sequel in patients with apparently cured Visceral Leishmaniasis (VL), the causative organism being *L. donovani.* In terms of its etiopathogenesis, it is possibly the most challenging variant of Leishmaniasis ([@bib16]; [@bib59]). As patients with PKDL harbour parasites in their dermal lesions that are easily accessible to sand flies, they act as disease reservoirs and play a major role in the transmission cycle ([@bib29]; [@bib28]). With a view to eliminating VL, from South Asia, the governments of Bangladesh, India and Nepal convened to establish a Regional Kala-azar Elimination Programme (KAEP), presently targeted for 2020 ([@bib59]). An important component of the KAEP is active surveillance so as to identify potential disease reservoirs, the key contributors being asymptomatic cases of VL and patients with PKDL.

Although PKDL is confined to South Asia and East Africa (mainly Sudan), they have several differences in that in South Asia, approximately 5--10% of apparently cured VL patients develop PKDL, whereas in Sudan it is 50--60%, and often concomitant with VL ([@bib6]; [@bib45]; [@bib57], [@bib58]). Furthermore, in Africa it appears as papular, macular, maculopapular, nodular or plaque-like lesions, and mostly heal spontaneously within 6 months to 1 year of their appearance ([@bib21]). In contrast, in South Asia, PKDL is not self-healing and presents in two distinct clinical forms, i.e. a combination of macules, papules and/or nodules, referred to as 'polymorphic PKDL' or as hypopigmented patches referred to as 'macular PKDL' ([@bib45]), and the former was earlier considered to represent over 90% of PKDL cases ([@bib36]; [@bib45]; [@bib16]). With implementation of active case surveillance in West Bengal, a huge number of macular cases were unearthed, that translated into the conventional ratio of polymorphic: macular becoming almost 1:1, i.e. macular PKDL now constitute nearly 50% of the PKDL population burden ([@bib51]). Unlike polymorphic PKDL, macular cases pose a diagnostic dilemma as owing to the minimal presence of detectable parasites, diagnosis is solely by clinical features, and their hypopigmented lesions are often indistinguishable from other hypopigmentary disorders like vitiligo, pitryasis versicolor or leprosy ([@bib51]). Furthermore, the hypopigmentation persists even after elimination of parasites, and therefore quantification of parasite load becomes a critical objective parameter of efficacy. In recent studies, the macular variant was less responsive to Liposomal Amphotericin B ([@bib31]), suggesting possible differences in host-parasite interactions, emphasizing the need for considering treatment stratification.

An ongoing debate regarding the role of macular cases in disease transmission was resolved by [@bib28] who in a proof-of-concept experiment established that both maculopapular and nodular PKDL lesions played a definitive role in transmission, thus countering the conventional belief that macular and papular forms pose a lesser threat than nodular PKDL. Furthermore, as both nodular and macular variants were demonstrated to be infectious to sand flies, it was recommended that treatment be accorded regardless of lesion type or disease duration ([@bib29]). In Indian PKDL, the cellular immune responses till date have always been analysed as a single entity and differences if any, between macular and polymorphic forms of PKDL remain poorly explored. The two forms differed in their proportion of activated CD4 and CD8 T-cells in the circulation ([@bib26]), but their status at the lesional sites are yet to be defined. Similarly, histopathological studies comparing the two forms of PKDL has been conducted ([@bib52]), but data comparing the immunopathology of polymorphic vs. macular variants is yet to emerge. Therefore, the immune pathways that underpin the pathogenesis of PKDL continue to remain a subject of considerable debate, with data on the macular component being fragmentary in nature. Accordingly, this study aimed to delineate and compare the *in-situ* immune profile of the two variants of PKDL in terms of their overall histopathology, especially with regard to distribution and characterization of the cellular infiltrate. Furthermore, the proliferation status of cells in the lesions were assessed in terms of Ki67 along with chemokines responsible for homing of macrophages (CCL2/7) and B-cells (CXCL13).

2. Materials and methods {#sec2}
========================

2.1. Reagents {#sec2.1}
-------------

Reagents were from Sigma Aldrich (St. Louis, Mo, USA) except anti-human CD4 (clone 4B12), CD8 (clone C6/144B), CD1a (clone 010), CD68 (clone PG-M1), HLA-DR (clone TAL.1B5), CD20 (clone L26), Ki67 (clone MIB-1), secondary detection system EnVision™ G\|2 System/AP-Rabbit/Mouse (Permanent Red), EnVision™ FLEX Mini Kit, High pH (DAB + chromogen), EnVision™ FLEX Target Retrieval Solution (Dako, Glostrup, Denmark), QIAmp DNA Mini kit (Qiagen, Hilden, Germany), SYBR Green qPCR Master Mix (Applied Biosystems, Grand Island, NY, USA) and Bio-Plex Pro™ Human Chemokine Panel 40-Plex (BioRad, Hercules, CA, USA).

2.2. Study population {#sec2.2}
---------------------

Patients clinically diagnosed with PKDL (n = 40) were recruited from the Dermatology outpatient departments of School of Tropical Medicine/Calcutta Medical College/Institute of PG Medical Education & Research, Kolkata (2007-date) or following active field surveys conducted in Malda, Dinajpur and Birbhum districts of West Bengal by active surveillance (2014-date, [@bib51]). The initial diagnosis was based on clinical features, a prior history of VL, rK-39 positivity, or if they resided in an area endemic for VL; subsequently, diagnosis was confirmed by ITS-1 PCR and/or Giemsa staining done on a lesional biopsy ([@bib9]). Healthy volunteers (n = 10) were recruited from non-endemic and endemic areas and were negative for anti-leishmanial antibodies as tested by ELISA. A dermal biopsy (4 mm) was obtained using a punch biopsy from any lesional site.

2.3. Histopathology {#sec2.3}
-------------------

Formalin fixed paraffin embedded (FFPE) tissues were sectioned (3 μm), placed on poly L-lysine coated slides and examined by Hematoxylin and Eosin (H&E) for overall histopathology and Giemsa stained for detection of Leishman Donovan (LD) bodies. The cellular infiltrate was scored semi-quantitatively as 1 = mild, 2 = moderate, 3 = severe and 4 = very severe \[1 = 0--25 cells/mm^2^; 2 = 26--50 cells/mm^2^; 3 = 51--75 cells/mm^2^; 4= \>75 cells/mm^2^\] ([@bib32]). A scoring was developed for LD bodies, wherein 1--10 parasites/1000 fields = 1+, 1--10 amastigotes/100 fields = 2+, 1--10 amastigotes/10 fields = 3+, 1--10 amastigotes/field = 4+, 10--100 amastigotes/field = 5 + and \>100 amastigotes/field = 6+. Five fields were manually counted under a light microscope (EVOS FL Cell Imaging System, Waltham, MA, USA) at 1000X magnification and the average was taken.

2.4. Immunohistochemistry {#sec2.4}
-------------------------

FFPE sections were deparaffinised in xylene and rehydrated using descending grades of alcohol (100-70%) and distilled water. After heat induced epitope retrieval at pH 6 or pH 9, the slides were incubated with appropriate dilutions of primary antibody (1:100 for CD1a, 1:50 for CD68, CD8, CD20, 1:40 for HLA-DR, CD4, 1:25 for Ki67) for 1 h, washed with Tris-buffered saline containing 0.05% Tween-20 (0.02M, pH 7.4, TBS-T) and incubated with EnVision™ G\|2 System/AP-Rabbit/Mouse (Permanent Red) or EnVision™ FLEX Mini Kit, High pH (DAB + chromogen) as per the manufacturer\'s protocol and counter stained with hematoxylin. Sections from human lymph nodes, gut and skin from healthy individuals served as positive controls ([@bib32]). For healthy controls, 4 mm skin biopsies were obtained from laboratory volunteers (n = 4) or foreskin of males undergoing voluntary circumcision (n = 6). Five fields were manually counted under a light microscope at 400X magnification, the average taken and expressed as cells mm^−2^. To minimize bias, two blinded investigators independently evaluated the slides.

2.5. Quantification of circulatory CCL2, CCL7 and CXCL13 {#sec2.5}
--------------------------------------------------------

Plasma levels of CCL2, CCL7 and CXCL13 were measured (diluted 1:4), using a multiplex detection kit (BioRad, Hercules, CA, USA) as per the manufacturer\'s protocol. Data was acquired in a Luminex 200 Labmap system (Luminex, Austin, TX, USA) and analysed using Bio-Plex Manager software version 6.2.

2.6. Measurement of parasite load by real time PCR (rtPCR) {#sec2.6}
----------------------------------------------------------

For measurement of parasite load, a standard curve was generated by adding a defined number of *Leishmania* parasites sourced from a *L. donovani* strain (ranging from 10 to 1 × 10^5^) to blood (180 μl) sourced from a healthy control. Real-time PCR was performed using specific primers for minicircle kDNA (116bp, forward 5′-CCTATTTTACACCAACCCCCAGT-3\'and reverse 5′-GGGTAGGGGCGTTCTGCGAAA-3′). Briefly, DNA extraction was performed according to the manufacturer\'s instructions from a skin biopsy collected in phosphate-buffered saline (20 mM, pH 7.4), excised into small pieces, and DNA eluted in 50 μL of DNA elution buffer. DNA (1 μl) was then added to a 19 μl reaction mixture containing SYBR Green Master mix and 400 nM of each primer. Two negative controls were used i.e. DNA from a healthy donor (no amplification), and a reaction mixture with water instead of the template DNA (no template). The number of parasites was extrapolated from the standard curve and final parasite load determined as the number of parasites/μg genomic DNA. Parasite load \<10 (C~T~ value being equivalent to NTC) was given an arbitrary value of 1 ([@bib31]).

2.7. Ethics statement {#sec2.7}
---------------------

The study received approval from the Institutional Ethics Committee of School of Tropical Medicine, Kolkata and Institute of Post Graduate Medical Education and Research, Kolkata and all experiments were performed in accordance with relevant guidelines and regulations. Individuals or their legally acceptable representative (if \< 18 years) gave a written informed consent. Informed consent was also obtained to publish after maintaining patient confidentiality information/images in an online open-access publication.

2.8. Statistical analysis {#sec2.8}
-------------------------

Results were expressed as median (Interquartile range, IQR) and data analysed between groups by Kruskal wallis test followed by Dunn\'s multiple comparison test for non-parametric data, while paired data were analysed using Student\'s t-test (for parametric data). Correlation was by Pearsons correlation for parametric data and Spearman\'s rank correlation for nonparametric data using GraphPad Prism software (version 5.0, GraphPad software Inc., La Jolla, CA, USA), p \< 0.05 being significant.

3. Results {#sec3}
==========

Active surveillance for PKDL unearthed a substantial proportion of macular PKDL and altered the conventional demographic scenario of PKDL, with the ratio of polymorphic:macular PKDL changing from 9:1 ([@bib36]; [@bib45]) to almost 1:1 ([@bib51]). Accordingly, the study population included patients with polymorphic (n = 20) and macular PKDL (n = 20). Amongst the polymorphic cases, 7 were obtained following passive surveillance and 13 following active surveillance, whereas all 20 macular cases were by active case detection. The median age, in years, was comparable between the two groups ([Table 1](#tbl1){ref-type="table"}), but in the polymorphic variant, there was a male preponderance which was absent in the macular cases ([Table 1](#tbl1){ref-type="table"}). Only one patient did not give a prior history of VL ([Table 1](#tbl1){ref-type="table"}). Regarding their treatment for VL, the polymorphic cases received Sodium antimony gluconate (SAG, 18/19) and one received Miltefosine. However, in the macular group, treatment was with SAG (n = 11), Miltefosine (n = 7) or Liposomal Amphotericin B (LAmB, n = 2).Table 1Study population.Table 1CharacteristicsPatients with PKDLHealthy controls (n = 10)Polymorphic (n = 20)Macular (n = 20)Age (years)[a](#tbl1fna){ref-type="table-fn"}25.50(19.00--38.75)17.50(10.00--33.00)4(2.75--26.25)Sex ratio (M:F)2.3:11:1.54:1Disease duration (years)[a](#tbl1fna){ref-type="table-fn"}0.83(0.42--4.00)0.75(0.30--2.00)NAInterval between VL and PKDL (years)[a](#tbl1fna){ref-type="table-fn"}5.00(3.00--7.00)3.00(2.00--4.00)NA[^1][^2]

In terms of distribution of lesions, there were lesions distributed asymmetrically in the polymorphic cases and predominantly on the sun exposed areas e.g. chin, nose, ears, lips and neck and occasionally on the limbs ([Fig. 1](#fig1){ref-type="fig"}a), and the number of lesions ranged from 10 to 12 ([Fig. 1](#fig1){ref-type="fig"}a). However, in the macular variant, lesions were generally symmetrically distributed ([Fig. 1](#fig1){ref-type="fig"}b), and diffusely scattered all over the body (head, neck, trunk, upper and lower limbs), [Fig. 1](#fig1){ref-type="fig"}b.Fig. 1**a.** Representative profiles of patients with polymorphic PKDL showing distribution of lesions.**b.** Representative profiles of patients with macular PKDL showing distribution of lesions**c.** Scatter plots showing parasite load (number of parasites/μg of genomic DNA) in patients with polymorphic (filled circle, n = 20) and macular (filled square, n = 20) PKDL. Each horizontal bar represents the median value.**d.** Representative profile of a Giemsa stained dermal section of a patient with polymorphic PKDL showing amastigotes (indicated by black arrows, 1000X magnification).Fig. 1

All patients were ITS-1 PCR positive and quantification of the parasite load by qPCR, showed that the median parasite number was 20.8 fold higher in the polymorphic group being 177348(11966-380513) vs. 8506(3572--67166)/μg genomic DNA, p \< 0.05, [Fig. 1](#fig1){ref-type="fig"}c. In polymorphic lesions, Leishman-Donovan (LD) bodies were identified ([Fig. 1](#fig1){ref-type="fig"}d), whereas no LD bodies were detected in macular cases, even when the parasite load was high. In majority of the polymorphic cases (14/20, 70%), LD body score was 5 + while in the rest, score was 4+. In polymorphic PKDL, the number of LD bodies correlated positively with the cell infiltration (cells/mm^2^), r = 0.44.

3.1. Distribution of cellular infiltrate {#sec3.1}
----------------------------------------

In both variants, there was a diffuse inflammatory cellular infiltrate which was primarily in the dermis in polymorphic cases, whereas in the macular variant, it was patchy, perivascular and periappendageal ([Fig. 2](#fig2){ref-type="fig"}a). The infiltrate in both variants comprised of lymphocytes, macrophages and plasma cells in the ratio of 4:5:1. In 70% of the polymorphic cases, the infiltrate occupied almost the entire dermis, whereas in the macular variant, it was present usually as clusters in the papillary dermis ([Fig. 2](#fig2){ref-type="fig"}a). The density of the cellular infiltrate in polymorphic PKDL ranged from moderate to severe, whereas in macular PKDL it was mild or sparse, median(IQR) being 2(1--3) vs. 1(1-1), [Fig. 2](#fig2){ref-type="fig"}b. In both types, the extent of the cellular infiltrate (cells/mm^2^) strongly correlated with the parasite load, being r = 0.54, p \< 0.05 in the polymorphic cases ([Fig. 2](#fig2){ref-type="fig"}c) and r = 0.73, p \< 0.001 ([Fig. 2](#fig2){ref-type="fig"}d) in the macular cases. With treatment, both variants demonstrated a pronounced decrease in the cell infiltrate ([Fig. 2](#fig2){ref-type="fig"}a). A narrow band of clear, sub-epidermal Grenz zone was evident in 13/20 polymorphic cases, but was limited to only 7/20 in the macular group ([Fig. 2](#fig2){ref-type="fig"}e). In both the clinical variants of PKDL, there was absence of epitheloid granulomas with giant cells ([Fig. 2](#fig2){ref-type="fig"}a). Also, unlike leprosy, the neural Schwann cells were unaffected and did not harbour parasites; furthermore, these patients reported no loss of sensation.Fig. 2**a.** Representative profiles of H&E stained sections from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL at disease presentation and post treatment (10X and 40X magnification).**b.** Scatter plots showing the dermal infiltration score of healthy controls (filled circle, n = 7), patients with polymorphic (filled square, n = 20) and macular (filled triangle, n = 20) PKDL. Each horizontal bar represents the median value.**c.** Correlation of parasite load (no. of parasites/μg genomic DNA) in patients with polymorphic PKDL with their cellular infiltration (cells/mm^2^).**d**. Correlation of parasite load (no. of parasites/μg genomic DNA) in patients with macular PKDL with their cellular infiltration (cells/mm^2^).**e**. Representative histological profile from a dermal biopsy of a patient with polymorphic PKDL showing epidermal thinning, presence of a clear Grenz zone, hyperkeratosis and papillomatosis (10X magnification). Representative histological profile from a dermal biopsy of a patient with macular PKDL showing epidermal thinning and follicular plugging (10X magnification). Scatter plots of epidermal thickness (μm) in healthy controls (filled circle, n = 8), patients with polymorphic (filled square, n = 10) and macular (filled triangle, n = 8) PKDL. Each horizontal bar represents the median value.**f**. Representative IHC profiles of Ki67 from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL; gut mucosal tissue served as a positive control (40X magnification).Fig. 2

3.2. Epidermal changes {#sec3.2}
----------------------

In polymorphic and macular PKDL, lesions in the epidermis demonstrated hyperkeratosis, focal papillomatosis, epidermal thinning and follicular plugging ([Fig. 2](#fig2){ref-type="fig"}e, [Table 2](#tbl2){ref-type="table"}) in varying degrees; hyperkeratosis was more frequently present in the polymorphic vs. macular cases \[14/20 vs. 8/20, 31.41(22.62--58.72)μm vs. 21.95(14.37--30.81)μm, p \< 0.05, [Fig. 2](#fig2){ref-type="fig"}e\]. Similarly, papillomatosis and elongation of rete ridges was more frequently evident in polymorphic (15/20, 75%) *vis-a-vis* macular cases (8/20, 40%), [Fig. 2](#fig2){ref-type="fig"}e, [Table 2](#tbl2){ref-type="table"}. In terms of epidermal thickness, it was significantly decreased in polymorphic cases as compared to healthy controls, 62.21(56.71--67.41) vs. 91.60(68.49--120.10) μm, p \< 0.01; the scenario was similar in macular cases \[52.37(39.98--60.78) μm, p \< 0.001\], [Fig. 2](#fig2){ref-type="fig"}e. Treatment translated into epidermal thickening, both in polymorphic \[102.90(43.04--157.4) μm\] as well as macular PKDL \[80.6(39.98--60.78) μm\]. However, hyperkeratosis persisted in 60% of the polymorphic and 70% of the macular cases ([Fig. 2](#fig2){ref-type="fig"}a).Table 2Histopathological changes in polymorphic and macular PKDL.Table 2FeaturesPolymorphic PKDLMacular PKDLHyperkeratosisMore frequent (14/20)Less frequent (8/20)PapillomatosisMore frequent (15/20)Less frequent (8/20)Epidermal AtrophyPresentPresentFollicular PluggingPresentPresentSub-epidermal clear Grenz zoneMore frequent (13/20)Less frequent (7/20)Intensity of dermal cell infiltrateModerate to severeMild to moderateDistribution of cell infiltrateDiffuse, occupying the entire dermisPatchy perivascular and periappendageal, mainly in the papillary dermisLeishman-Donovan (LD) bodiesPresentAbsentComposition of the cell infiltrateMajority macrophages and lymphocytes and few plasma cellsMostly macrophages and plasma cells with very few lymphocytesGranulomaAbsentAbsent

3.3. Absence of proliferation at the dermal site in polymorphic and macular PKDL {#sec3.3}
--------------------------------------------------------------------------------

The expression of Ki-67 protein is associated with cell proliferation and is present during all active phases of the cell cycle ([@bib50]). Both polymorphic and macular PKDL did not demonstrate any positive staining for Ki67, thus indicating that the cells at the dermal lesions are non-proliferative in nature and have been homed to the lesional sites ([Fig. 2](#fig2){ref-type="fig"}f).

3.4. Langerhans cells decreased in polymorphic and macular PKDL {#sec3.4}
---------------------------------------------------------------

Dendritic cells (DCs) are the major immune sentinels in the skin and are present as epidermal Langerhans cells (LC) and dermal DC (dDC), both identifiable by staining with CD1a ([@bib32]). In both variants, there was a loss of characteristic spindle shaped cells with dendritic processes, and instead cells had a more circular pattern ([Fig. 3](#fig3){ref-type="fig"}a). At disease presentation, polymorphic PKDL demonstrated a significant 3.07 fold decrease in LCs as compared to healthy controls \[6.00(3--10.65) vs. 18.40(17.75--20.60) cells mm^−2^, p \< 0.001\]; similarly, the macular cases showed a significant 1.74 fold decrease \[10.60(9.10--11.50) cells mm^−2^, p \< 0.05\], [Fig. 3](#fig3){ref-type="fig"}b.Fig. 3**a**. Representative IHC profiles of CD1a^+^ dendritic cells from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL (40X magnification).**b**. Scatter plots showing the status of epidermal and dermal CD1a^+^ dendritic cells in healthy controls (filled circle, n = 6), patients with polymorphic (filled square, n = 10) and macular (filled triangle, n = 10) PKDL; each horizontal bar represents the median value.**c**. Representative IHC profiles of HLA-DR^+^ cells from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL (10X magnification)**d**. Scatter plots showing the status of HLA-DR^+^ cells in healthy controls (filled circle, n = 7), patients with polymorphic (filled square, n = 9) and macular (filled triangle, n = 8) PKDL. Each horizontal bar represents the median value.Fig. 3

With regard to dermal DCs, as compared to healthy controls there was a substantial 9.06 fold decrease in the polymorphic variant \[1.70(0.75--3.00) vs. 15.40(13.85--17.90) cells mm^−2^, p \< 0.01\] and a 3.85 fold decrease in macular cases \[4.00(0.50--7.10) cells mm^−2^, p \< 0.01\] ([Fig. 3](#fig3){ref-type="fig"}a and b). However, irrespective of the variant, the dendritic cells poorly correlated with parasite load (r = 0.03 and 0.01) with regard to polymorphic and macular PKDL respectively.

3.5. Decrease in HLA-DR was greater in macular PKDL {#sec3.5}
---------------------------------------------------

Antigen presenting cells use HLA-DR, a major MHC (major histocompatibility complex) class II cell surface receptor to present processed antigenic peptides for recognition by T-cells. In polymorphic PKDL, the HLA-DR expression was lower than healthy controls \[8.20(6.80--10.30) vs. 13.80(7.00--18.20) cells mm^−2^\], whereas in the macular group, it was significantly lowered by 4.3 fold as compared to controls \[3.20(1.35--5.55) cells mm^−2^, p \< 0.01\], [Fig. 3](#fig3){ref-type="fig"}c and d. In both variants, the correlation between HLA-DR^+^ cells and parasite load was weak, being r = 0.17 and 0.03 with regard to polymorphic and macular PKDL respectively.

3.6. Increased presence of CD68^+^ macrophages limited to polymorphic PKDL {#sec3.6}
--------------------------------------------------------------------------

Pathogens including *Leishmania* must evolve ways to circumvent the antimicrobial strategies adopted by macrophages ([@bib5]). In Indian PKDL, an increased presence of alternatively activated macrophages at lesional sites has been demonstrated ([@bib36]), but the study focused on the polymorphic variant. At disease presentation, there was an increased infiltration of CD68^+^ cells in polymorphic and macular PKDL, being 10.75 fold higher in polymorphic PKDL as compared to healthy controls, 60.2(15.5--99.8) vs. 5.6(2.5--10.4) cells mm^−2^, p \< 0.05 and only 2.3 fold in macular PKDL \[13.1(2.25--19.05) cells mm^−2^, [Fig. 4](#fig4){ref-type="fig"}a and b\]. The parasite load correlated positively with CD68^+^ cells in polymorphic PKDL (r = 0.59), whereas in macular PKDL it correlated negatively (r = −0.41). In terms of disease duration, CD68^+^ cells showed a negative correlation in polymorphic (r = −0.41) and macular (r = −0.47) PKDL. The levels of chemokines, CCL2 (MCP-1) and CCL7, responsible for the dermal homing of macrophages were raised by 3.7 and 1.7 fold respectively as compared to healthy controls being 415.60(183.80--903.50) pg/ml vs. 112.80(58.50--223.50) pg/ml, p \< 0.01 and 39.23(31.43--58.78) pg/ml vs. 23.19(21.86--32.69) pg/ml, p \< 0.01 respectively ([Fig. 4](#fig4){ref-type="fig"}c and d).Fig. 4**a.** Representative IHC profiles of CD68^+^ cells from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL (10X magnification).**b**. Scatter plots showing the status of CD68^+^ cells in healthy controls (filled circle, n = 6), patients with polymorphic (filled triangle, n = 10) and macular (filled square, n = 10) PKDL. Each horizontal bar represents the median value.**c**. Scatter plots indicating plasma levels of CCL2 in healthy controls (filled circle, n = 9) and patients with PKDL (filled square, n = 12). Each horizontal bar represents the median value.**d**. Scatter plots indicating plasma levels of CCL7 in healthy controls (filled circle, n = 9) and patients with PKDL (filled square, n = 12). Each horizontal bar represents the median value.Fig. 4

3.7. Increased CD8^+^ T-cells only in polymorphic PKDL {#sec3.7}
------------------------------------------------------

Irrespective of the clinical variant, there was a preponderance of CD8^+^ over CD4^+^ T-cells in dermal lesions, with the CD4^+^ subset being minimally present in almost all biopsies analysed ([Fig. 5](#fig5){ref-type="fig"}a and b). The proportion of CD8^+^ T-cells increased by 16 fold in the polymorphic group as compared to healthy controls \[31.9(21.85--38.95) vs. 2.0(0.75--6.05) cells mm^−2^, p \< 0.01\]. However, in the macular form, CD8^+^ T-cells were completely absent in some cases (n = 4) or comparable with healthy controls \[1.8(0.6--2.75) vs. 2.0(0.75--6.05) cells mm^−2^\], ([Fig. 5](#fig5){ref-type="fig"}c and d). In polymorphic PKDL, the number of CD8^+^ T-cells at the lesional site correlated positively with the parasite load (r = 0.61), but macular PKDL showed a negative correlation, r = −0.41.Fig. 5**a**. Representative IHC profiles of CD4^+^ T-cells from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL (10X magnification).**b**. Scatter plots showing the status of CD4^+^ T-cells in healthy controls (filled circle, n = 6), patients with polymorphic (filled triangle, n = 10) and macular (filled square, n = 10) PKDL. Each horizontal bar represents the median value.**c**. Representative IHC profiles of CD8^+^ T-cells from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL (10X and 40X magnification).**d**. Scatter plots showing the status of CD8^+^ T-cells in healthy controls (filled circle, n = 6), patients with polymorphic (filled triangle, n = 10) and macular (filled square, n = 10) PKDL. Each horizontal bar represents the median value.**e**. Representative IHC profiles of CD20^+^ B-cells from dermal biopsies of a healthy control, patient with polymorphic and macular PKDL (40X magnification).**f**. Scatter plots showing the status of CD20^+^ B-cells in healthy controls (filled circle, n = 3), patients with polymorphic (filled triangle, n = 6) and macular (filled square, n = 5) PKDL. Each horizontal bar represents the median value.**g**. Scatter plots showing plasma levels of CXCL13 in healthy controls (filled circle, n = 10) and patients with PKDL (filled square, n = 9). Each horizontal bar represents the median value.Fig. 5

3.8. Increase in CD20^+^ B-cells greater in polymorphic PKDL {#sec3.8}
------------------------------------------------------------

B-cells, as detected by CD20, increased in both variants as compared to healthy controls, being 6.5 fold higher in polymorphic cases \[7.80(3.65--11.25) vs. 1.20 (0.80--1.80) cells mm^−2^, p \< 0.05\] and 4 fold higher in the macular cases \[4.80(2.20--7.00) cells mm^−2^\], [Fig. 5](#fig5){ref-type="fig"}e and f. Additionally, the circulating levels of CXCL13, the B-lymphocyte chemoattractant was elevated, being 18.28(14.26--22.88) vs. 11.68(9.88--13.92) pg/ml in healthy controls, p \< 0.01 ([Fig. 5](#fig5){ref-type="fig"}g).

4. Discussion {#sec4}
=============

PKDL since its identification by Brahmachari in 1922 has been clubbed as one entity with the polymorphic variant reigning supreme constituting \>90% of cases, while the remaining 10% were macular cases who present with innocuous hypopigmented lesions and importantly, do not actively seek treatment. It is only following implementation of the ongoing active surveillance programme that awareness of this neglected disease burden was enhanced ([@bib51]). Furthermore, considering the overlapping features with other dermal variants of Leishmaniasis, it is important to distinguish the immunopathological characteristics of the two variants of Indian PKDL from that of CL or Sudanese PKDL. Accordingly, this study aimed to delineate the cellular milieu of the two variants, and provide more information on macular PKDL *vis-à-vis* its well defined polymorphic counterpart ([@bib16]; [@bib58]; [@bib45]).

Irrespective of the geographical zone, dermal Leishmaniasis is distributed mainly in the face, neck, upper and lower extremities i.e. areas exposed to the bite of sandflies ([@bib47]). However, in PKDL this does not hold true as lesions are more diffuse and in the polymorphic variant appear primarily on sun-exposed areas ([Fig. 1](#fig1){ref-type="fig"}a), similar to Sudanese PKDL, where the distribution of lesions often mirrors the clothing habits of those affected ([@bib21]). This has been attributed to these areas having greater exposure to UV light ([@bib21]) and suggested the possibility of Vitamin D polymorphism ([@bib35]). However, with regard to the macular cases, this logic fails as their lesions are symmetrically distributed all over the body ([Fig. 1](#fig1){ref-type="fig"}b).

Studies on the overall histopathology of PKDL have established that akin to CL and African PKDL ([@bib22]), there is a moderate to dense inflammatory cell infiltrate with lymphocytes being the predominant cellular component ([@bib52]). However, this information is based on the polymorphic variant, as the infiltrate in macular cases was sparse and patchy comprising of lymphocytes, histiocytes and a few plasma cells ([Fig. 2](#fig2){ref-type="fig"} a,b) in concordance with previous studies ([@bib52]; [@bib44]). This indicates that despite the parasite being *L. donovani*, the two variants generate immunologically distinct immune responses, similar to tuberculoid and lepromatous variants of leprosy ([@bib12]). Furthermore, in view of the clinical features of polymorphic or macular PKDL overlapping with lepromatous or tuberculoid leprosy, as also its geographical overlap, it is important to differentiate to avoid unnecessary treatment. Unlike leprosy, where the infiltrate is patchy with a peri-appendageal location and a predilection for nerve bundles, in PKDL, the neural Schwann cells are usually unaffected with no loss of sensation. However, in terms of distribution, polymorphic PKDL was similar to CL and lepromatous leprosy, as the infiltrate encompassed the entire dermis ([@bib45]; [@bib19]). However, in macular PKDL, the infiltrate remained confined to the upper section of the dermis ([Fig. 2](#fig2){ref-type="fig"}a and b). Furthermore, associated changes in the epidermis and dermis such as hyperkeratosis and focal papillomatosis were more frequently observed in the polymorphic variant ([Fig. 2](#fig2){ref-type="fig"}e, [Table 2](#tbl2){ref-type="table"}) whereas focal necrosis, a consistent feature in CL, was absent in both variants of PKDL.

The formation of granulomas results from an inflammatory interplay between a persistent, non-degradable antigen and the host\'s immune response, and translates into the release of pro-inflammatory cytokines as also chemokines along with activation of dendritic cells that transports the microbial antigen(s) to the lymph nodes ([@bib4]). This is followed by migration of activated T-cells to the granuloma, culminating in enhancement of the microbicidal activity of macrophages and limiting of the disease ([@bib10]). Classical examples are self-healing L-CL ([@bib54]; [@bib19]) and the African PKDL ([@bib22]), but was notably absent in Indian PKDL. IL-10 is known to inhibit granuloma formation as endorsed in a model of tuberculosis ([@bib8]) and similarly, in lepromatous leprosy, IL-10 induced by type I interferons (IFN α/β) limits formation of granulomas ([@bib53]). This possibly holds true for Indian PKDL as both variants demonstrated raised levels of IL-10 ([@bib33]; [@bib15]).

Detection of LD bodies in slit skin smears or tissue biopsies is the gold standard and has been augmented by quantification of parasite load by qPCR ([@bib31]). In CL and African PKDL there was no correlation between the number of amastigotes and areas of inflammation and necrosis ([@bib49]; [@bib22]) whereas in the Indian variant, the dense, diffuse cell infiltrate in polymorphic PKDL correlated positively with parasite load ([Fig. 2](#fig2){ref-type="fig"} c,d) and the presence of LD bodies. However, in all biopsies from macular cases, LD bodies were minimally present, even in cases where the parasite burden was comparable with polymorphic PKDL ([Fig. 1](#fig1){ref-type="fig"}c and d). This is in agreement with previous studies ([@bib52]; [@bib46]), and suggests that perhaps the parasites are migrating deeper into the dermis, reasons for which remain unanswered.

The skin, as a vital immune surveillance organ, continuously interacts with various infectious agents and generates an immune response dependent on the local inflammatory infiltrate ([@bib30]), with key contributors being dendritic cells via efficient induction of T-cell activation ([@bib20]). In patients with CL caused by *L. braziliensis,* the density of Langerhans cells (LCs) could be linked with disease severity ([@bib13]). Conversely, in Indian PKDL, a decreased presence of LCs was reported in the polymorphic variant ([@bib32]) and was mirrored to a lesser extent in macular cases ([Fig. 3](#fig3){ref-type="fig"}a and b). This was similar to Sudanese PKDL, where a similar scenario has been reported in terms of the dendritic cell number and morphology ([@bib21]). As UVB rays can directly damage epidermal E-LCs ([@bib7]), it could account for their decrease being more pronounced in polymorphic lesions that appear mainly in sun exposed areas ([Fig. 1](#fig1){ref-type="fig"}a).

*Leishmania*-macrophage interactions are multifaceted and are dependent on the cytokine milieu and species ([@bib11]), as for example, in L-CL, the enhanced presence of Th1-associated cytokines leads to macrophages acquiring a heightened effector function and demonstrate a classically activated phenotype, as evidenced by CD68^+^ macrophages with an elevated iNOS ([@bib49], [@bib39]). Conversely, in the more severe and chronic DCL, a Th2 milieu is present, along with alternative activation of macrophages with elevation of the arginase pathway that impedes protective immunity and promotes parasite growth ([@bib14]). Similarly, in PKDL, the polymorphic variant demonstrated an increased presence of alternatively activated macrophages ([@bib32]; [@bib36]), which correlated positively with parasite load and supported disease chronicity ([Fig. 4](#fig4){ref-type="fig"} a,b). However, in macular PKDL, the proportion of CD68^+^ macrophages was substantially lower than the polymorphic variant ([Fig. 4](#fig4){ref-type="fig"}b), and in fact, correlated negatively with parasite load; their activation status remains to be delineated. Therefore, it may be proposed that in macular PKDL, the lower proportion of monocytes/macrophages accounts for their lower parasite load and translates into a milder disease profile. In view of the lower degree of infiltration of monocytes/macrophages at the lesional site in macular PKDL, it may have an impact on the lesional concentration of Liposomal Amphotericin B, as validated in a murine model of CL ([@bib56]). Therefore, it is important that clinical trials be undertaken with a cohort representing both types of PKDL.

Antigen presenting cells use HLA-DR (MHC-II) molecules to present processed antigen to T-cells and in self healing CL, HLA-DR positivity was demonstrated in keratinocytes and granulomas ([@bib43]). Similarly, in African PKDL, most cells in the dermis are HLA-DR^+^ ([@bib22]), possibly facilitating its self resolution. However in the Indian counterpart, the proportion of HLA-DR positivity was substantially decreased in both variants ([Fig. 3](#fig3){ref-type="fig"}c and d), the decrease being more prominent in the macular cases, possibly due to the lower infiltration of CD68^+^ macrophages ([Fig. 4](#fig4){ref-type="fig"}a and b) and CD1a^+^ dendritic cells ([Fig. 3](#fig3){ref-type="fig"}a and b).

The nature of T-cell responses often mirrors the disease outcome, and depending on their functional responses can be protective or deletorius ([@bib37]). In Old World CL caused by *L. major*, CD4^+^ T-cells dominate the lymphocyte infiltrate ([@bib39]; [@bib18]), whereas in the more severe forms of New World CL caused by *L. braziliensis*, cytotoxic CD8^+^ T-cells predominate ([@bib38]). This CD8 T-cell cytotoxicity further activates the NLRP3 mediated inflammasome cascade leading to IL-1β release, accounting for the chronic inflammation ([@bib38]). In Indian PKDL, there was an increased CD3 positivity ([@bib17]), but a consistent absence of CD4^+^ T-cells was noted ([Fig. 5](#fig5){ref-type="fig"}a and b). This was in contrast to the self-healing Sudanese PKDL, where CD4^+^ T-cells predominate ([@bib22]), and it can therefore be proposed that this absence of CD4^+^ T-cells accounts for their inability to self heal. Furthermore, the study by [@bib17] was mainly on the polymorphic variant and included only one macular case. In this study, differences emerged between the two variants regarding their proportion of CD8^+^ T-cells which were in abundance only in polymorphic lesions ([Fig. 5](#fig5){ref-type="fig"}c and d) and possibly account for their exaggerated inflammatory response. Conversely, the reduced presence of T-cells in macular PKDL possibly accounts for their relatively milder, cell mediated immune response ([Fig. 5](#fig5){ref-type="fig"}c and d).

In terms of the humoral immune response, B cells and plasma cells are present in lesional tissue, the proportion being higher in ulcerating CL (L-CL) than non-ulcerating chronic lesions of DCL ([@bib55]). These CD20^+^ cells are found usually in the middle of the dermis and do not differ between early and late lesions of CL ([@bib49]). However, in African PKDL, B-cells are far fewer in number and in a minority of patients. In the Indian counterpart, the proportion of circulating CD19^+^ B-cells are decreased ([@bib34]) whereas, in dermal lesions of both variants, an increased expression of CD20^+^ B-cells was demonstrated ([Fig. 5](#fig5){ref-type="fig"} e,f). These B-cells possibly support parasite persistence via facilitation of antibody mediated opsonisation of parasites into macrophages, as evident in experimental leishmaniasis ([@bib23]).

Infection with *Leishmania* induces chemokines to promote recruitment of leukocytes to lesional sites ([@bib40]) and was corroborated in PKDL wherein increased levels of skin homing CCL17 and CCL22 was associated with an increased presence of CD8^+^ T-cells at the lesional sites ([@bib33]). In CL, CCL2 (Monocyte Chemoattractant Protein −1 or MCP-1) has been shown to play an important role in mediating recruitment of macrophages, monocytes, NK cells and other CCR2 expressing leukocytes ([@bib2]; [@bib48]), while CCL7 has been reported to attract Th2 cells to the lesional sites during infection with *L. major* ([@bib25]). In PKDL, the consistent absence of Ki67 expression in dermal lesions in both variants confirmed dermal homing ([Fig. 2](#fig2){ref-type="fig"}f) and was corroborated by raised levels of CCL2, CCL7 and CXCL13, that accounted for the increased recruitment of macrophages and B-cells ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}g).

The scientific advances in our knowledge of the immune response in Leishmaniasis have allowed for excellent immunochemotherapeutic options to be developed and validated in animal models. However, the absence of an animal model for PKDL, as also limited availability of patients has led to its treatment remaining empirical and poorly defined ([@bib42]). The natural history of PKDL suggests that it is not a static but a dynamic condition in which the parasite load, onset and appearance of the clinical presentation, as also tendency to self-heal vary with the developing immune response. What has been proven beyond doubt is that the immunological features of PKDL differ from VL, the systemic 'forerunner', in several aspects. It has been proposed that PKDL originates as an immune reconstitution inflammatory syndrome, resulting from a loss of immune suppression following drug treatment for VL ([@bib3]). If VL is to be eliminated in South Asia, PKDL patients must be treated effectively and requires availability of robust data regarding the immunopathology of dermal lesions. As the development of PKDL is in all likelihood a host driven phenomenon, immune manipulation can be considered at several time points, (a) preventing the development of VL to PKDL (b) using immunomodulators like Miltefosine and (c) use of vaccines alone or combined with immuno-chemotherapy that may well have a therapeutic and/or prophylactic role ([@bib41]). This study has delineated important differences between the polymorphic and macular variant, and could serve as a resource to underpin future mechanistic studies for guiding clinical research with a view towards achieving the critical goal of elimination of Leishmaniasis.
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[^1]: M = Male; F= Female; NA= Not applicable; PKDL= Post Kala-azar Dermal Leishmaniasis; VL= Visceral Leishmaniasis.

[^2]: Values are expressed as median (IQR).
